ROS1 and non-small cell lung carcinoma: Both crizotinib and ceritinib are recommended by the NCCN guidelines as first-line treatment for patients with advanced ROS1-positive NSCLC.[19] In East Asian patients with ROS1-positive advanced NSCLC, the ORR and mPFS after crizotinib treatment were 71.7% and 15.9 months, respectively.[20]Therefore, crizotinib remains the best first-line treatment option for such patients, especially for those from China, followed by the next generation of TKIs when the disease progresses.[21] However, no approved second-line targeted therapies are available once resistance to crizotinib has developed.